Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. - Wikidata - awgldk - TriplyDB

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

http://www.wikidata.org/entity/Q46014175

about

Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors The impact of HIF1α on the Per2 circadian rhythm in renal cancer cell lines.VHL, the story of a tumour suppressor gene.Development of novel DNA vaccine for VEGF in murine cancer model Emerging molecular classification in renal cell carcinoma: implications for drug development.Stratification of clear cell renal cell carcinoma (ccRCC) genomes by gene-directed copy number alteration (CNA) analysis Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma.Tissue-based research in kidney cancer: current challenges and future directions.VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy.What can molecular pathology contribute to the management of renal cell carcinoma?Kidney cancer pathology in the new context of targeted therapy.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature.Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis.Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era.Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.Sunitinib.Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel–Lindau (VHL) disease: clinical outcome and patterns of radiological response Clinicopathologic Significance of Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review

P2860

Q26825512-002AD3B3-05FE-445F-9F90-2777963F8463 Q26852437-F9C610B1-49BD-44C5-AB23-4E39C5A35047 Q27851432-100B1B18-E5AE-4576-923F-08BF55E8444F Q28728573-E6B6F3BF-82E4-46D1-974A-409B4C74E6AB Q30671049-20E28FFB-AEE9-4951-8D43-3CACE08F8210 Q34055338-B78CB9EA-9435-4737-97A7-2D35D7AD1EB5 Q34379470-D8D0539B-A6F7-4228-ABD7-AD1D970A972D Q34455226-73A124A3-2893-4078-8458-C45815289E81 Q35056226-E19DDBB4-1CCB-4AA0-A6DB-3E5E476E44FC Q36084718-2EFFAAEA-B5E2-4E64-AB94-30F57ECA1BFD Q36367103-DE2A3D24-A0D3-486E-B8F3-8641EB4AFD25 Q36477265-8D9CD705-83C9-47D8-9918-A35C6AA15924 Q36893510-350A9441-8B50-4E4F-82E9-A7C8DBE26926 Q36982059-8DFE783B-D698-4961-8AF5-993A5160697A Q37038901-EE8B04E6-B16A-44A1-92B6-212D1D7753D1 Q37069569-F4DDE54A-F6DE-49BA-83D7-36BD40E870E8 Q37393004-DC47BB58-FFAA-4BE8-BAB9-92F2E81E414A Q37401553-795E1A37-64EC-4015-968B-4E62AE837362 Q37730440-E6916279-CA58-43ED-A54A-452B4388DB22 Q37864528-4D1DFE3E-81BD-40F2-BD23-B07E6A94330F Q37890209-8977BE3C-8635-42BA-A4A2-9DF40BB78F4B Q38196855-7F862BFF-0FDA-4FBB-9685-C15305C2642B Q38334611-D96093F5-1090-4BE0-9F61-D062D43DDAFC Q39095254-6FAC52F3-1DC0-4B7D-89B5-E16633C0DB6A Q39199929-78E76144-5788-49C1-8713-FC87948A15D1 Q39395931-E0ADF767-8654-48A5-A5A2-4679D87138AC Q39398836-CA4E2997-4F41-45DF-9B9E-F5131EEA5A90 Q39657263-CC7AE88F-CC6D-4D0F-9962-865819AC369F Q41919666-01C3E743-0D30-4039-A812-DBEC7B5968CD Q45945323-678E41D1-A952-4A0B-BDE3-7A7FC6844A3D Q46957688-28340DB2-BF46-4D34-9C55-4A71DA6A43CE Q52582783-1E81FB8E-9FB6-4DE4-A0F8-2E1D17E437F5 Q57578654-20151EA8-E387-432F-9A7E-0196F20ADD56 Q58701873-E9EFB3B1-4150-4565-A5FE-B50F0CA475A1

P2860

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

http://www.wikidata.org/entity/Q46014175

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Clinical response to therapy t ...... Von Hippel-Lindau gene status.

@en

Clinical response to therapy t ...... Von Hippel-Lindau gene status.

@nl

type

label

Clinical response to therapy t ...... Von Hippel-Lindau gene status.

@en

Clinical response to therapy t ...... Von Hippel-Lindau gene status.

@nl

prefLabel

Clinical response to therapy t ...... Von Hippel-Lindau gene status.

@en

Clinical response to therapy t ...... Von Hippel-Lindau gene status.

@nl

P1433

Q46014175-0CFC25AB-44AF-4897-8896-413C29EE734E

P1476

Q46014175-0429AC38-30EF-4C49-9798-B8BDC796EAE3

P2093

Q46014175-0DF20EC5-7631-42B1-9009-52646043F1A6

Q46014175-10A738B4-D439-4BB9-BB31-B674DA9760B9

Q46014175-153BEF11-3B55-4B25-AC99-C7F91D9CAEBB

Q46014175-7552CE5A-0FB2-47BB-8C12-ADE8450A53D0

Q46014175-814DDFD9-08A9-4C62-AED2-72519C1D8DB5

Q46014175-C5542241-E085-41E7-87FE-252CD1E3714C

Q46014175-CDE9133E-6319-4338-BBE0-06B79DC3A078

Q46014175-F16C9E61-0453-4D70-87D2-651505A3307F

Q46014175-FC95616C-3BA1-43B1-8842-E36D7808D8CD

P2860

Q46014175-059572A3-539C-4D6C-A7EE-95C4FE3DEE8D

Q46014175-0A49C04F-0982-40BF-B8BF-32151A1AB8B5

Q46014175-0E86B537-6292-4CEA-BB9A-C111588670A1

Q46014175-2E8D8D0D-AAFE-4C65-9800-F0C55CCC53FB

Q46014175-3A9742F9-80CA-4AD0-956E-2995AB2E237B

Q46014175-3C8997CE-73EF-496D-ADDA-E19DC1FADC0C

Q46014175-3ED80909-D53F-4DC4-9B90-4F78FDD882F3

Q46014175-47746FFC-9093-431E-B24F-DBE7BD92A1D6

Q46014175-6D0FA985-E6D0-4F21-831F-3ECFEB50537E

Q46014175-7041B3D9-C641-4931-A49F-3519DDFC60BF

P304

Q46014175-77DBC855-23B8-4AD0-8922-354F56151E9F

P31

Q46014175-535BE4E5-11AF-4129-9007-4E184A13D3C2

P356

Q46014175-D26A21A3-7CC0-4865-826E-4026DF8DF4FE

P433

Q46014175-18D11271-BF22-42C9-8F96-FDC0DBEA98B6

P478

Q46014175-9D29AAF4-4668-4702-9255-473F9D3D5283

P577

Q46014175-87F53642-C900-4A21-8948-84A25ACCAC42

P698

Q46014175-BCFF2B7B-929A-4E3F-AB47-AB5345B99D77

P921

Q46014175-3BB86035-1CE3-432B-8C76-45467DC6E317

Q46014175-A366146A-55D7-4001-9378-C6142AC7A396

P356

J.1464-410X.2006.06376.X

P1433

BJU International

P1476

Clinical response to therapy t ...... Von Hippel-Lindau gene status.

@en

P2093

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Eric J Small

http://www.w3.org/2001/XMLSchema#string

Erich Jaeger

http://www.w3.org/2001/XMLSchema#string

Frederic M Waldman

http://www.w3.org/2001/XMLSchema#string

Jeffery Simko

http://www.w3.org/2001/XMLSchema#string

Karen Chew

http://www.w3.org/2001/XMLSchema#string

Kristen Fong

http://www.w3.org/2001/XMLSchema#string

Nancy Sein

http://www.w3.org/2001/XMLSchema#string

Vivian Weinberg

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

Interleukin 6 induces the expression of vascular endothelial growth factor

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study

VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Hypoxia-mediated regulation of gene expression in mammalian cells.

Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

P304

756-762

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1464-410X.2006.06376.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16827904

http://www.w3.org/2001/XMLSchema#string

P921